Humana is at a critical juncture. The company is expanding its Medicare Advantage strategy, but leadership changes are raising investor concerns.
Humana has the highest exposure to Medicare Advantage among major insurers. Aging demographics offer growth opportunities. High enrollment growth is expected in 2026.
The company is diversifying its Stars ratings. This could boost profitability, but risks remain.
Leadership transition increases operational risks. The retirement of George Renaudin creates uncertainty.
Financial projections vary. Scenarios show EPS ranging from $11 to $17.
The Centerwell unit contributes to growth. Vertical integration provides a competitive edge.
Overall, Humana has strong potential, but execution risks require attention.
